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INTRODUCTION
The term co-induction has been used to describe the practice of administering 
a small dose of sedative or another anaesthetic agent10 to reduce the dose of 
induction  agent  required.  The  term  co-induction  of  anaesthesia  has  been 
applied to the use of two or more drugs to induce anaesthesia.11.The term was 
introduced in 1986 to describe the unplanned induction of anaesthesia by non-
anaesthetically trained personnel practicing sedation, unplanned anaesthesia in 
unsuitable environment  leading to several  fatalities.  Currently,  planned co-
induction  of  anaesthesia  is  practiced  by  anaesthesiologists  exploiting  drug 
interaction particularly  synergism.3.The arguments  for  co-induction are  two 
fold.  First,  to  improve  the  balance  of  desired  versus  adverse  effects  and 
secondly to reduce cost. When used this way midazolam has been shown to 
reduce the  dose  of  propofol  required  to  induce  anaesthesia  by  up to  50% 
without affecting recovery profile 33
.
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The  technique  of  administering  two  or  more  hypnotic  drugs  to  facilitate 
induction  and  maintenance  of  general  anaesthesia  has  gained  considerable 
popularity.  One rationale  for  combining drugs in anaesthesia  is  to achieve 
more “specific target responses, while minimizing side effects and facilitating 
rapid and predictable recovery”.
As  yet,  no  single  intravenous  anaesthetic  drug  can  effectively  and  safely 
provide hypnosis,  analgesia  and amnesia.  Thus  intelligent  combinations  of 
hypnotics  and  opioids  are  necessary,  especially  for  total  intravenous 
anaesthesia  (TIVA).  Inescapable  interactions  occur,  most  of  which  are 
synergistic and should be evaluated for the optimal care of the patient. This 
synergism varies considerably according to the different drugs, the different 
endpoints of anaesthesia and the differently combined dosage of both agents. 
M. A. Khan, et al observed co-induction of anaesthesia with midazolam 0.02 
mg.kg-1  and  thiopentone  3  mg.kg-1  was  associated  with  a  smooth  and 
significantly  faster  induction,  better  airway  control,  greater  haemodynamic 
stability and lesser incidence of untoward effects compared to midazolam 0.02 
mg.kg-1 and thiopentone 2 mg.kg-1 or thiopentone 4 mg.kg-1 alone.
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The  most  common  disadvantages  with  propofol  are  its  greater  cost  as 
compared to thiopentone is high incidence of pain on injection (50 - 100%) 
and relatively more hypotension as compared to thiopentone. 
Short  TG. et  al, in  1991,studied  the dose of  propofol  required to  produce 
anaesthesia was reduced by 52% in the presence of midazolam .The cause of 
synergism was not clear but may have been interaction at CNS GABA(A) 
receptors.
Amrein R  , et al   .in 1995 investigated midazolam and propofol as potential 
partners. The relationship between desired effects and adverse effects could be 
improved by skillful use of the synergism between midazolam and propofol. 
Co-induction of anaesthesia and co-administration in long-term sedation can 
offer improvements in therapeutic situations compared with monotherapy.
Whitlam   JG .etal   in 1995 studied the use of midazolam and propofol with or 
without either fentanyl or alfentanil is probably the principal technique for the 
induction of day-case anaesthesia A major advantage is that by reducing the 
dose  of  propofol  there  is  less  chance  of  the  severe  bradycardia  that  is 
sometimes  associated  with  the  combined  use  of  propofol  and  opioids, 
although  this  can  be  prevented  by  vagolytic  agents.  However,  the  use  of 
opioids increases the incidence of post-operative nausea and vomiting.
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Howard-Griffin, R. et al   in 1997 compared the co-induction with midazolam-
alfentanil-thiopentone  and  midazolam-alfentanil-propofol.  Following  pre-
induction doses of midazolam 0.04 mg.kg-1 and alfentanil 10 microgm/.kg, 
Patients received equipotent doses of either thiopentone or propofol. It was 
concluded  that  using  these  doses  propofol  is  superior  to  thiopentone  for 
laryngeal mask airway insertion when using a co-induction technique.
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AIM OF STUDY
This study compares the midazolam co-induction and propofol predosing
with regard to 
1. Dose of propofol required for induction.
2. Blood pressure variability during induction
3. Heart rate variability during induction
For adult patients undergoing elective surgeries
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ANATOMY AND PHARMACOLOGY OF GABA RECEPTORS
STRUCTURE AND FUNCTION
The  receptor  is  a  multimeric transmembrane  receptor that  consists  of  five 
subunits arranged around a central pore. The receptor sits in the membrane of 
its neuron at a synapse. The ligand GABA is the endogenous compound that 
causes  this  receptor  to  open;  once  bound  to  GABA,  the  protein receptor 
changes  conformation  within  the  membrane,  opening  the  pore  in  order  to 
allow chloride ions (Cl-) to pass down their electrochemical gradient. Because 
the  chloride  ion  concentration  is  high  outside  of  the  cell,  opening  of  the 
channel pore results in an influx of chloride into the cell, thus making it more 
negative (hyperpolarizing it). The GABAA channel opens quickly and thus 
contributes to the early part of the inhibitory postsynaptic potential (IPSP).
 
  7
GABA is the chief inhibitory neurotransmitter in the mammalian brain. Along 
with glycine--that primarily has effects in the spine, brainstem and retina--it is 
responsible  for  the vast  majority  of  all  inhibitory neurotransmission  in the 
central nervous system (CNS). Between 20-50% of all central synapses use 
GABA  as  their  transmitter.  The  enzyme  responsible  for  the  formation  of 
GABA from the amino acid glutamate is glutamic acid decarboxylase 
There were once  thought  to  be three types  of  receptors  for  GABA in the 
mammalian  CNS,  designated  A,  B,  and  C.  The  GABA  A and  GABA  C 
receptors are GABA-gated chloride ion-conducting channels while the GABA 
B receptor is a member of the seven transmembrane helix-containing, guanine 
nucleotide-binding receptor  G-protein-coupled receptors. The GABA A and 
GABA C receptors  were  initially  distinguished  by  their  sensitivity  to  the 
ligand  bicuculline with the former being antagonized by it  while the latter 
were insensitive. While varieties of the GABA A receptor are found all over 
the CNS, the GABA C receptors are primarily found in the retina.
 It has become increasingly clear since the mid-1990s that the GABA A and 
GABA C receptors  are  simply  variants  of  the same GABA-gated chloride 
channel that should be simply denoted by the “GABA A” receptor design
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The GABA A receptor is a member of the Cys-loop ligand-gated ion channel 
super  family  which also  includes  the glycine,  5-hydroxytryptamine  (5-HT, 
serotonin),  and  nicotinic  acetylcholine  receptors.  Receptors  of  this  super 
family consist of pentamers of homologous subunits arranged around a central 
ion-conducting channel. There are 19 different subunit genes—not including 
alternatively-spliced variants such as the short (S) and long (L) forms of the 
1-6, γ1-3,αγ2 subunit—divided into eight subunit classes: β1-3, θ, ρ1-2, δ, π, 
ε (listed according to sequence relatedness). It is presumed that these subunits 
all arose as a result of gene duplications of an original sequence. Within a 
class of subunits there is approximately 70% sequence identity, and between 
subunit classes there is approximately 30% sequence identity .The majority of 
GABA A receptor subtypes in the mammalian brain contain at least one α, β, 
and γ subunit .Most GABA A receptors consist of assemblies of these three 
subunit classes.
The  most  abundantly  expressed  isoform  of  the  GABA  A  receptor  in  the 
mammalian brain is composed of α1, β2, and γ2. The likely stoichiometry is 
two  α,  two  β  and  one  γ  subunit  arranged  around  the  ion  channel  anti-
clockwise γ-β-α-β-α as seen from the synaptic cleft 
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Ligand binding to the GABA A receptor
GABA  binding  (to  the  “GABA  site”)  activates  the  GABA  A  receptor, 
allowing chloride ions to flow through the central pore and hyperpolarize the 
neuron, decreasing the probability that it will propagate an action potential. In 
this activity, the GABA A receptor does not differ  from any other ligand-
gated ion channels.  However,  among neurotransmitter  receptors,  GABA A 
receptors  are  unique  in  the  number  of  ligands  that  allosterically  modulate 
receptor  function  GABA  A  receptors  can  exist  in  at  least  three  different 
conformations:  open,  closed,  and  desensitized  .Up  to  14  different  ligand 
binding sites have been proposed to account for the modulation of GABA .
Binding to the receptor can alter the conformation in such a way as to enhance 
or diminish the chloride flux in response to GABA binding. Some anesthetics 
(etomidate, pentobarbitone) both enhance chloride flow in response to GABA 
binding  as  well  as  activating  it  directly  in  the  absence  of  GABA.  Other 
ligands, cage convulsants of the picrotoxin type, bind within the central pore, 
occluding  the  channel  and  preventing  chloride  flow no  matter  what  other 
ligand subsequently binds. Some of these compounds have seen commercial 
use as pesticides.
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Subunits There  are  numerous  subunit  isoforms for  the  GABAA receptor, 
which  determine  the  receptor’s  agonist  affinity,  chance  of  opening, 
conductance, and other properties .There are six types of α subunits, three β's, 
three γ's, as well as a δ, an ε, a π, a θ, and three ρs .Five subunits can combine 
in different ways to form GABAA channels, but the most common type in the 
brain has two α's, two β's, and a γ .The receptor binds two GABA molecules, 
somewhere between an α and a β subunit 
Agonists and antagonists
Other ligands (besides GABA) interact with the GABAA receptor to activate it 
(agonists), to inhibit its activation (antagonists) or to increase or decrease its 
response  to  an  agonist  (positive  and negative  allosteric  modulators).  Such 
other ligands include benzodiazepines (increase pore opening frequency; often 
the ingredient of sleep pills and anxiety medications),  barbiturates (increase 
pore  opening  duration;  used  as  sedatives),  and  certain  steroids,  called 
neuroactive steroids.
Among  antagonists  are  picrotoxin  (which  blocks  the  channel  pore)  and 
bicuculline  (which  occupies  the  GABA  site  and  prevents  GABA  from 
activating  the  receptor).  The  antagonist  flumazenil is  used  medically  to 
reverse the effects of the benzodiazepines.
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A useful property of the many agonists and some antagonists is that they often 
have  a  greater  interaction  with  GABAA receptors  which  contain  specific 
subunits.
This allows one to determine which GABAA receptor subunit combinations 
are prevalent in particular brain areas and provides a clue as to which subunit 
combintations may be responsible  for  behavioral  effects  of drugs acting at 
GABAA receptors. Among the behavioral effects of such drugs are relief of 
anxiety  (anxiolysis),  muscle relaxation,  sedation,  anticonvulsion,  and 
anesthesia
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PHARMACOLOGY OF PROPOFOL
2,6-bis(1-methylethyl)-phenol 
Physicochemical characteristics:
Molecular weight—178.28 
pH Propofol emulsion: 7 to 8.5.
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PHARMACODYNAMICS
Hemodynamic effects: 
Propofol's hemodynamic effects are generally more pronounced than those of 
other  intravenous  anesthetic  agents  Arterial  hypotension28,  with  readings 
decreased by as much as 30% or more has been reported, possibly due to 
inhibition of sympathetic vasoconstrictor nerve activity 44  Hypotensive effects 
are generally proportional to dose and rate of administration of propofol(8), 
and may  be  potentiated  by  opioid  analgesics4  Endotracheal  intubation  and 
surgical  stimulation  may  increases  in  heart  rate and/or  blood pressure10 to 
greater than baseline values, which occur frequently with other agents, are not 
as  significant  with  propofol,  possibly  due  to  central  sympatholytic  and/or 
vagotonic effects4. Propofol may also decrease systemic vascular resistance 10 
myocardial blood flow, and oxygen consumption4. The mechanism of these 
effects may involve direct vasodilation 9and negative inotropy 10 Effects such 
as  decreased  stroke volume and cardiac output  have been demonstrated  in 
some studies32
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Respiratory effects: 
Propofol  is  a  respiratory  depressant,  frequently  producing  apnea  that  may 
persist  for  longer  than  60  seconds15,  depending  on  factors  such  as 
premedication8, rate of administration 10 , dose administered, and presence of 
hyperventilation or hyperoxia. In addition, propofol may produce significant 
decreases in respiratory rate  , minute volume, tidal volume 6, mean inspiratory 
flow  rate,  and  functional  residual  capacity14.  These  respiratory  depressant 
effects  may  be  the  result  of  depression  of  the  central  inspiratory  drive  as 
opposed to a change in central timing 14.The ventilatory depressant effects of 
propofol may be counteracted by painful surgical stimulation 06.
Cerebral effects: 
Propofol  decreases  cerebral  blood  flow15,  cerebral  metabolic oxygen 
consumption  and  intracranial  pressure  and  increases  cerebrovascular 
resistance. It does not appear to affect cerebrovascular reactivity to changes in 
arterial carbon dioxide tension 15
Other effects: 
Preliminary findings suggest that in patients with normal intraocular pressure, 
propofol  decreases  intraocular  pressure18 by  as  much  as  30  to  50%.  This 
decrease may be associated with a concomitant decrease in systemic vascular 
resistance 7
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Clinical studies have shown that propofol does not cause significant signs of 
histamine  release  22or  significant  increases  in  plasma  immunoglobulin  or 
complement  C  3  levels22.  Respiratory  resistance  after  tracheal  intubation  is 
lower when propofol is used for induction of anesthesia than when thiopental 
or high-dose etomidate is used for induction of anesthesia 14
Although  propofol  has  the  potential  for  affecting  adrenal  steroidogenesis 
(18)it does not appear to block cortisol and aldosterone secretion in response 
to surgical stress or adrenocorticotropic hormone (ACTH) 8 in clinical practice 
Although transient decreases in plasma cortisol concentrations have occurred, 
these reductions have not been sustained 8
Propofol appears to have no analgesic activity   . In addition, animal studies 
have demonstrated no significant effect on coagulation profiles 
Propofol has antiemetic properties  19 Anesthesia with propofol results in less 
nausea and vomiting than anesthesia  with desflurane,  enflurane,  isoflurane, 
methohexital, nitrous oxide, or thiopental.
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Pharmacokinetics
Distribution: 
Propofol  is  rapidly  4and extensively27distributed in the body.  It  crosses the 
blood-brain barrier quickly  4, and its short duration of action is due to rapid 
redistribution from the CNS to other tissues 27, high metabolic clearance 4 and 
high lipophilicity 
Volumes of distribution 4 
Initial apparent (Vol D ): 13 to 76 liters (L) 
Steady-state (Vol DSS ): 171 to 349 L 
Elimination (Vol D ): 209 to 1008 L 
Steady-state (Vol  DSS  ) in pediatric patients: 9.5 ± 3.71 liters per kg of  body 
weight (L/kg) 
Protein binding: 
Very high (95 to 99%) {04} 
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Metabolism(27)
Liver  glucuronate  & sulfate  conjugation  ->  excreted  in  urine  (70% in  24 
hours, 90% in 5 days).
Metabolites probably inactive.
Cl  exceeds  hepatic  blood  flow.  Extrahepatic  metabolism  has  been  shown 
during liver transplantation.
Half-life: 
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Distribution: 
Two distribution phases(27)— 
Rapid—2 to 4 minutes 
Slower—30 to 64 minutes 
Blood-brain equilibration half-life: 2.9 minutes (4)
Terminal elimination half-life is 3 to 12 hours
Prolonged administration of propofol may result in a longer duration (28)
Note:   The  long terminal  elimination  half-life  of  propofol  does  not  reflect 
elimination,  as more than 70% is eliminated during the first  2 phases (28) 
Some investigators believe that the second exponential phase half-life (30 to 
64 minutes) best explains the properties of propofol in clinical practice (27)
Onset of action: 
Loss of consciousness occurs rapidly and smoothly, usually within 40 seconds 
(one  arm-brain  circulation  time)  from the  start  of  intravenous  injection  of 
propofol  {10}   . Loss of consciousness is dependent on the dose administered, 
the rate of administration, and the extent of premedication (16)
Plasma concentrations 
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Propofol concentrations of 1.5 to 6 mcg per mL (8.42 to 33.66 micromoles per 
liter [micromoles/L]) will maintain hypnosis, although needs vary with type of 
surgery and use of other anesthetic agents {04} . 
Duration of action: 
Mean duration following a single bolus dose of 2 to 2.5 mg per kg of body 
weight is 3 to 5 minutes (18)
Time to recovery (40)
Recovery from anesthesia with propofol is rapid  , with minimal psychomotor 
impairment (15) . Emergence following induction (with 2 to 2.5 mg of propofol 
per kg) and maintenance (with 0.1 to 0.2 mg of propofol per kg per minute) 
for up to 2 hours occurs in most patients within 8 minutes  {01}  {04}  {11}  . If an 
opioid has been used, recovery may take up to 19 minutes (55)
Recovery  occurs  faster  than  recovery  following  the  use  of  etomidate, 
methohexital, midazolam , or thiopental (25). When anesthesia has included 
use of an opioid with propofol, recovery has occurred more quickly than with 
similar use of etomidate (6) , midazolam (39), or thiopental (25).
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Elimination: 
Renal (35) approximately 70% of a dose is excreted in the urine within 24 
hours after administration, and 90% is excreted within 5 days. Clearance of 
propofol ranges from 1.6 to 3.4 liters per minute in healthy 70 kg patients. As 
the  age  of  the  patient  increases,  total  body  clearance  of  propofol  may 
decrease. Clearance rates ranging from 1.4 to 2.2 liters per minute in patients 
18 to 35 years of age have been reported, in contrast to clearance rates of 1 to 
1.8 liters per minute in patients 65 to 80 years of age (48)
Note:  Pharmacokinetic  parameters  of  propofol  appear  to  be unaffected  by 
gender, obesity, chronic hepatic cirrhosis (46) and chronic renal failure (35)
Propofol is indicated for the induction of  general anesthesia in adults and in 
pediatric  patients  greater  than  3  years  of  age.  (31)  It  is  also  indicated  for 
maintenance  of  anesthesia  utilizing  balanced  techniques  with  other 
appropriate agents such as opioids and inhalation anesthetics (41) in adults 
and pediatric patients greater than 2 months of age. (31)
 
  21
INDICATIONS AND USES 
Propofol is indicated for the induction of  general anesthesia in adults and in 
pediatric  patients  greater  than  3  years  of  age.  (31).It  is  also  indicated  for 
maintenance  of  anesthesia  utilizing  balanced  techniques  with  other 
appropriate agents  such as opioids and inhalation anesthetics  in adults and 
pediatric patients greater than 2 months of age (21).
Sedation—Propofol is indicated for sedation in critically ill patients confined 
to  intensive  care  units  (8)—Propofol  is  indicated  to  produce  sedation  or 
amnesia as a supplement to local or regional anesthetics (8), and in diagnostic 
procedures, such as endoscopy (53). 
Anti emetic -in dose of 10 to 20mgs
Anti pruritic- in dose of 20 to 30 mgs 
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Side/Adverse Effects
Incidence more frequent
Apnea 29
bradycardia 32
hypotension 23
Incidence less frequent or rare 
Hypertension 7
perioperative myoclonia, rarely including opisthotonus 8
pancreatitis 30abdominal pain)—symptoms may not occur until after discharge 
from medical care following use of propofol 
Involuntary muscle movements, temporary 28
nausea and/or vomiting  
pain, burning, or stinging at injection site 
Note:  Excitatory movements reportedly occur more often than with thiopental 
but less often than with etomidate   or methohexital.  Pain is usually mild and 
short-lived  , and may be decreased by using the larger veins of the forearm or 
the  antecubital  fossa  16or  a  dedicated  intravenous  catheter   .  Pain  may  be 
decreased by prior intravenous injection of 10 to 20 mg of lidocaine  . Post-
injection thrombosis or phlebitis is rare  . 
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Incidence less frequent or rare 
Abdominal cramping  
Cough, dizziness, fever, flushing, headache 
Hiccups, tingling, numbness, or coldness at injection site 
Clinical effects of overdose 
Acute
Cardiovascular depression 
Respiratory depression 
Treatment of overdose 
Specific treatment: Discontinuation of propofol 01. 
For respiratory depression: artificial ventilation with oxygen 01. 
For  cardiovascular  depression:  elevation  of  legs,  increasing  flow  rate  of 
intravenous fluids, and administration of pressor agents and/or anticholinergic 
agents 01
. 
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PHARMACOLOGY OF MIDAZOLAM HYDROCHLORIDE
C18H13ClFN3 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-Imidazo  (1,5-a)
(1,4)benzodiazepine
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Midazolam, a water-soluble imidazo benzodiazepine, has anxiolytic, sedative 
and anticonvulsive characteristics. These are based on its bond with receptors 
in the central nervous system; these receptors cause an increased inhibitory 
effect  of  g-aminobutyric  acid  (GABA).  Midazolam  is  lipid-soluble  in 
physiological pH and it reaches the central nervous system quickly.
It was first synthesized in 1976 by Fryer and Walser.
Midazolam is water soluble as the imidazole ring is open at low pH. When it 
is  in a solution with a pH greater  than 4,  the imidazole  ring closes and it 
becomes  much  more  lipid  soluble,  facilitating  its  rapid  uptake  into  nerve 
tissue. This partly accounts for its rapid onset of action and its high protein 
binding in the blood (up to 97%).
Molecular Weight 325.767 g/mol
Melting Point 159°C
H2O Solubility 40.0 mg/ml
State Solid (White Crystalline Powder)
LogP/Hphobicity 3.868
Half Life 2.2-6.8 hours
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Absorption Rapidly absorbed after oral administration (absolute 
bioavailability of the midazolom is about 36% and 
intramuscular injection is greater than 90%)
Protein Binding (%) 97%
Bio transformation Midazolam is primarily metabolized in the liver and gut by 
human cytochrome cyp34a to its pharmacologically 
active metabolite alpha hydroxymidazolam and 4-
hydroxymidazolam
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CLINICAL PHARMACOLOGY
Pharmacodynamics26
 Pharmacodynamic properties of midazolam and its metabolites,  which are 
similar  to  those  of  other  benzodiazepines,  include  sedative,  anxiolytic, 
amnesic  and  hypnotic activities.  Benzodiazepine  pharmacologic  effects 
appear to result from reversible interactions with the (gamma)-amino butyric 
acid (GABA)  benzodiazepine receptor in  the  CNS,  the  major  inhibitory 
neurotransmitter in the central nervous system. The action of midazolam is 
readily reversed by the benzodiazepine receptor antagonist, flumazenil. 
The effects of midazolam on the CNS are dependent on the dose administered, 
the route of administration, and the presence or absence of other medications. 
Following premedication with midazolam, time to recovery has been assessed 
using various measures, such as time to eye opening, time to extubation, time 
in the recovery room, and time to discharge from the hospital. Most placebo-
controlled trials (8 total) have shown little effect of midazolam on recovery 
time from general anesthesia48 however, a number of other placebo-controlled 
studies  (5  total)  have  demonstrated  some  prolongation  in  recovery time 
following  premedication with  oral midazolam.  Prolonged  recovery may be 
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related to duration of the surgical procedure and/or use of other medications 
with central nervous system depressant properties. 40
Partial  or  complete  impairment of  recall following  midazolam  has  been 
demonstrated  in  several  studies.  Amnesia  for  the  surgical experience was 
greater after midazolam when used as a premedicant than after  placebo and 
was generally considered a benefit. In one study, 69% of midazolam patients 
did not remember mask application versus 6% of placebo patients. 
Episodes of  oxygen desaturation,  respiratory depression, apnea, and airway 
obstruction have been reported following premedication (; the potential for 
such adverse events  are  markedly  increased when midazolam is  combined 
with  other  central nervous system depressing  agents  and  in  patients  with 
abnormal airway anatomy, patients with cyanotic congenital heart disease, or 
patients  with  sepsis or  severe  pulmonary disease (Concomitant  use  of 
barbiturates or other central nervous system depressants may increase the risk 
of  hypoventilation,  airway obstruction,  desaturation or  apnea,  and  may 
contribute to profound and/or prolonged drug effect. 
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Pharmacokinetics(26)
Absorption:  Midazolam is rapidly absorbed after  oral administration and is 
subject to  substantial  intestinal  and  hepatic first-pass  metabolism.  The 
pharmacokinetics of  midazolam  and  its  major  metabolite,  (alpha)-
hydroxymidazolam 
Distribution: The  extent  of  plasma protein binding  of  midazolam  is 
moderately  high  and  concentration independent.  In adults  and  pediatric 
patients older than 1 year, midazolam is approximately 97% bound to plasma 
protein,  principally  albumin.  In healthy volunteers,  (alpha)-
hydroxymidazolam is  bound to  the  extent  of  89%.,  the  mean steady-state 
volume of distribution ranged from 1.24 to 2.02 L/kg. 
Metabolism: Midazolam  is  primarily  metabolized  in  the  liver  and  gut by 
human cytochrome P450  IIIA4  (CYP3A4)  to  its  pharmacologic  active 
metabolite,  (alpha)-hydroxymidazolam,  followed  by  glucuronidation  of  the 
(alpha)-hydroxyl metabolite which is present in unconjugated and conjugated 
forms in  human plasma. The (alpha)-hydroxymidazolam glucuronide is then 
excreted in urine.
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 In a  study  in  which  adult volunteers  were  administered  intravenous 
midazolam  (0.1  mg/kg)  and  (alpha)-hydroxymidazolam  (0.15  mg/kg),  the 
pharmacodynamic  parameter values  of  the  maximum effect (E  max  )  and 
concentration eliciting  half-maximal  effect (EC  50  )  were  similar  for  both 
compounds. Midazolam is also metabolized to two other  minor metabolites: 
4-hydroxy metabolite (about 3% of the dose) and 1,4-dihydroxy  metabolite 
(about  1%  of  the  dose)  are  excreted  in  small  amounts  in  the  urine as 
conjugates. 
Elimination: The mean elimination half-life of midazolam ranged from 2.2 to 
6.8  hours  following  single  ,oral  doses  of  0.25,  0.5,  and  1.0  mg/kg  of 
midazolam  Similar  results  (ranged  from  2.9  to  4.5  hours)  for  the  mean 
elimination half-life were observed following IV administration of 0.15 mg/kg 
of midazolam (6 months to <16 years old). the  mean total  clearance ranged 
from 9.3 to 11.0 mL/min/kg. 
Renal Impairment: Although the pharmacokinetics of intravenous midazolam 
in adult patients with chronic renal failure differed from those of subjects with 
normal renal function,  there  were  no  alterations  in  the  distribution, 
elimination, or clearance of unbound drug in the renal failure patients. 
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Hepatic Dysfunction: Chronic  hepatic disease alters the  pharmacokinetics of 
midazolam. Following oral administration of 15 mg of midazolam, C max  and 
bioavailability values  were  43%  and  100%  higher,  respectively,  in  adult 
patients with hepatic cirrhosis than adult subjects with normal liver function. 
In the same patients with hepatic cirrhosis, following IV administration of 7.5 
mg of midazolam, the clearance of midazolam was reduced by about 40% and 
the elimination half-life was increased by about 90% compared with subjects 
with normal liver function. Midazolam should be titrated for the desired effect 
in patients with chronic hepatic disease.
Congestive  Heart  Failure:  Following  oral administration  of  7.5  mg of 
midazolam,  elimination half-life values  were  43% higher  in  adult  patients 
with congestive heart failure than in control subjects
Neonates:  has not been studied in pediatric patients less than 6 months of age. 
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SIDE EFFECTS: Dizziness,  headache and pain or redness at the injection 
site  fainting,  confusion,  mental/mood  changes,  trouble  breathing,  muscle 
twitching,  uncontrolled  movements,  however  unlikely.  Symptoms  include: 
throat discomfort, difficulty breathing, skin rash, hives, itching. 
Depending on its dose, midazolam can cause any stage of a  cardiovascular 
and  respiratory  depression.  High  i.v.  doses  have  caused  cardiac  and 
respiratory  arrest  with  lethal  consequences.  Usual  doses  normally  cause  a 
minor  decrease  of  the blood pressure  and oxygen saturation.  The  amnesia 
desired,  e.g.  for  endoscopies,  can  last  much  longer  than  the  intervention, 
sometimes  for  hours  (semi  consciousness).  Occasionally  daydreams  with 
sexual content occur. In addition to a multitude of central nervous symptoms 
(vertigo, dizziness, headaches, rarely hallucinations, etc.), midazolam can also 
cause  visual  disturbances  and  nausea.  Repeated  administration  (e.g.  as  a 
sleeping aid)  leads  to  tolerance  and dependence  within weeks;  withdrawal 
syndrome often occurs if the drug is discontinued abruptly.
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Midazolam: Interactions A dangerous central nervous sedation can develop 
if midazolam is combined with alcohol or other centrally sedative drugs (e.g. 
opioids). Cimetidine and ranitidine cause higher midazolam levels. 
Midazolam: Risk Groups   
Pregnant women: 
Even though a correlation between benzodiazepines and malformations is not 
safely established, midazolam should be avoided if possible.
Nursing mothers: 
Midazolam is eliminated through breast milk: better avoided
Children: 
Usual parenteral single dose: 0.08 to 0.15 mg/kg (maximum of 0.20 mg/kg). 
0.35 to 0.45 mg/kg can be given rectally.
Elderly people: 
Greatest  care is  indicated  in  the  elderly  (and  when  general  condition  is 
impaired): initially no more than 50% of the usual dose!
Renal failure: 
Dose reduction may be indicated (individual adjustment).
Liver insufficiency: 
Dose reduction may be indicated (individual adjustment).
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INDICATIONS AND USES 
1. Intramuscularlyorintravenouslyforpreoperative 
sedation/anxiolysis/amnesia; 
2.Intravenously as an agent for sedation/anxiolysis/amnesia prior to or during 
diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, 
gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, 
oncology procedures, radiologic procedures, suture of lacerations and other 
procedures either alone or in combination with other CNS depressants; 
3.Intravenously for induction of general anesthesia, before administration of 
other anesthetic agents. With the use of narcotic premedication, induction of 
anesthesia can be attained within a relatively narrow dose range and in a short 
period of time. Intravenous midazolm can also be used as a component of 
intravenous supplementation of nitrous oxide and oxygen (balanced 
anesthesia)
4. Continuous intravenous infusion for sedation of intubated and 
mechanically ventilated patients as a component of anesthesia or during 
treatment in critical care settings
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 REVIEW OF LITERATURE
Short  TG. et  al  in  1991  studied  interactions  between  IV  propofol  and 
midazolam  for  induction  of  anaesthesia  in  200  unpremedicated  female 
patients  undergoing  elective  gynaecological  surgery  using  end  points  of 
hypnosis  (loss  of  response  to  verbal  command)  and  anaesthesia  (loss  of 
response to 5-s transcutaneous tetanic stimulus)  and found that  synergestic 
interaction was found. The combination having 1.44 times the potency of the 
individual agents. The dose of propofol required to produce anaesthesia was 
reduced by 52% in the presence of midazolam. The cause of synergism was 
not clear but may have been due to interaction at CNS GABA(A) receptors.
McClune S. et al in 1992 compared synergestic interaction between propofol 
and midazolam in 140 ASA 1 and 2 female patients (18-60 years). Clinical 
end points included loss of response to command, loss of eye lash reflex and 
failure to respond to application of anaesthetic face mask. Administration of 
25% of ED 50 of midazolam followed by 50% of ED 50 of propofol resulted 
in loss of response to command in 50% of patients while 50% of ED 50 of 
midazolam followed by 25% of ED 50 of propofol had the same effect.
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Caba F. et al in 1993 studied the synergism of midazolam and propofol in the 
induction of anaesthesia. A double blind study of 90 ASA 1 and 2 women 
undergoing elective surgery revealed the ED 50 in propofol group was 1.56 
mg/kg  and  that  of  midazolam  group  was  0.24  mg/kg.  In  the  midazolam 
propofol group the ED 50 of midazolam was reduced approximately quarter 
and reduced dose was 0.068 mg/kg. 
Teh J  ,  Short TG  , et al .in 1994 tested the hypothesis that the “synergistic 
interaction which occurs when midazolam and propofol are combined for i.v. 
sedation is caused by an increase in the free plasma concentration of one of 
the drugs.” Six patients undergoing general anaesthesia received an infusion 
of propofol with the addition of an infusion of midazolam commenced 30 min 
later. Another six patients received an infusion of midazolam with the 
addition of an infusion of propofol 30 min later It was concluded that the 
observed synergism with this combination could not be explained solely by 
alteration in free plasma concentration of either of these drugs when they were 
administered together.
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Vinik HR  ,  et al .in 1994 tested the hypnotic effects of propofol, midazolam, 
alfentanil.  Their  binary  and  triple  combinations  were  studied  in  130 
unpremedicated patients in a randomized, double-blind fashion. The ability to 
open  eyes  on  verbal  command  was  used  as  an  end-point.  Dose-response 
curves  for  the  three  drugs  given  separately  and  in  combination  were 
determined with a probit procedure and the ED50 values were compared with 
an isobolographic analysis.  The ratios of a single-drug fractional dose to a 
combined fractional dose indicating the degree of superadditivity (synergism) 
were:1.4  for  propofol-alfentanil,  1.8  for  midazolam-propofol,  2.8  for 
midazolam-alfentanil, and 2.6 for propofol-midazolam-alfentanil. The results 
indicate  that  the  propofol-midazolam-alfentanil  interaction  produces  a 
profound hypnotic synergism which is not significantly different from that of 
the binary midazolam-alfentanil combination.
Amrein R  , et al   .in 1995 investigated midazolam and propofol as potential 
partners.  The  mechanism  of  action,  pharmacokinetic  properties, 
pharmacological effect, the way in which they interact at the receptor site, the 
differences  in  pharmaceutical  formulations,  the  side-effect  profiles  and 
economic considerations were compared. 
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Animal  experiments  and  clinical  pharmacology  studies  have  shown  that 
midazolam and propofol  have synergy with other centrally active drugs.  It 
could be expected that the relationship between desired effects and adverse 
effects could be improved by skilful use of the synergism between midazolam 
and propofol.
 Co-induction of anaesthesia and co-administration in long-term sedation can 
offer  improvements  in  therapeutic  situations  compared  with  monotherapy. 
These improvements are in terms of a more suitable effect  profile,  a more 
favorable ratio of desirable effects to side-effects, optimization of the time-
course of effects and reduced costs.
Elwood T  ,  et  al   .  in  1995 tested  the  hypothesis  that,  “in  the  presence  of 
alfentanil,  the  combination  of  midazolam  with  propofol  for  a  very  brief 
operative  procedure  would  not  affect  the  recovery  phase”.  64  outpatients 
scheduled  for  dilatation  and  curettage  received  placebo,  or  low-dose 
midazolam (0.03 mg.kg-1), or high-dose midazolam (0.06 mg.kg-1) iv, in a 
randomized  double-blind  manner.  They  then  received  alfentanil  10 
micrograms.kg-1 iv, followed by titrated doses of propofol iv for induction 
and maintenance of anaesthesia.
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  Outcome measures were: propofol dose (induction and maintenance), time 
until  eye-opening  to  command,  and  time  to  discharge-readiness.  Propofol 
induction dose was decreased by increasing doses of midazolam. Midazolam 
delayed the time to eye-opening but not time to discharge-readiness. It was 
concluded  that midazolam propofol co-induction in the presence of alfentanil 
delays eye-opening, but does not delay discharge after anaesthesia.
Martlew RA  , et al   .in 1996 determined the dose-response curves and 
effective doses of propofol for insertion of the laryngeal mask airway (LMA) 
in 50 unpremedicated children and in 60 children premedicated with 
midazolam, aged 3-12 yr. One of several doses of propofol was administered 
i.v. over 15 s to groups of 10 children, and conditions for LMA insertion were 
assessed at 60 s. The doses required for satisfactory LMA insertion in 50% 
and 90% of unpremedicated patients (ED50, ED90) were 3.8 mg kg-1 and 5.4 
mg kg-1, respectively; those for premedicated patients were 2.6 mg kg-1 and 
3.6 mg kg-1, respectively.
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Reinhart DJ, et al . in 1997 Compared the hemodynamics, efficacy, safety 
and postoperative recovery of patients following the use of either midazolam 
plus  propofol  or  placebo  plus  propofol  for  induction  and  maintenance  of 
general anesthesia for outpatient surgical procedures of less than two hours' 
duration.  The  study  included  203 ASA I,  II,  and III  patients  undergoing 
various  outpatient  surgical  procedures.  Concluded  that  concomitantly 
administered  midazolam  and  reduction-concentration  propofol  did  not 
exacerbate  the  well-described  hypotensive  effects  of  full-strength  propofol 
during induction of anesthesia.  The time to intubation was same  with the 
combination  of  midazolam/propofol  as  compared  with  propofol  alone. 
Recovery from the two regimens was not significantly different.  However, 
reduced  recall  of  perioperative  events  was  observed  more  often  in  the 
midazolam/propofol regimen compared with propofol alone.
Tighe,  K.  et  al  in  1997 studied   the  influence  of  co-induction  with 
midazolam  in  conjunction  with  propofol/alfentanil  anaesthesia  on 
postoperative psychomotor recovery. The study was placebo controlled and 
double  blind with patients  receiving  either  0.03 mg.kg-1  of  midazolam or 
saline 2 min before induction of anaesthesia.. 
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Patients  who  underwent  co-induction  with  midazolam  had  significantly 
impaired concentration and rapidity of response but improved accuracy and 
vigilance  when  compared  with  those  who  received  saline.  The  study 
confirmed that co-induction with a subanaesthetic dose of midazolam reduced 
the induction  dose  of  propofol  by  up  to  50%. It  was  concluded  that  co-
induction with midazolam reduces psychomotor recovery in the immediate 
postoperative phase following propofol infusion anaesthesia.
McAdam LC  ,  et al  in 1998 evaluated the interactions between propofol and 
midazolam in modulating GABA(A) receptor activity in embryonic 
hippocampal neurons. The effects of midazolam and propofol on peak current 
evoked by submaximal concentrations of GABA were studied using the patch 
clamp method. Isobolographic analysis was undertaken by constructing 
concentration-response curves for midazolam and propofol alone and then 
evaluating the potency of combinations of midazolam and propofol. In other 
experiments, the concentration of GABA was increased and flurazepam was 
substituted for midazolam. Isobolographic analysis confirmed that midazolam 
and propofol interact synergistically to enhance currents evoked by low 
concentrations of GABA (1 microM).
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 However, when the concentration of GABA was increased to 3 microM, the 
interaction  was additive.  The  interaction between flurazepam and propofol 
was also additive for enhancement of currents evoked by 3 microM GABA. It 
was  concluded  that  the  interaction  between  midazolam  and  propofol  was 
critically dependent on the concentration of GABA: Synergism was evident at 
low concentrations of GABA, but an additive interaction was apparent when 
the concentration of GABA was increased.  Changes in GABA(A) receptor 
function  may  underlie  the  synergistic  interaction  between  propofol  and 
midazolam for clinical effects such as hypnosis. The clinical implication of 
the results is that the benefits of synergism observed at one concentration ratio 
of these drugs may not be apparent at another
D. H. Conway, et al  in 2000 Investigated the influence of co-induction with 
remifentanil and midazolam on effect site propofol requirements at induction 
of anaesthesia using target-controlled infusions .in Sixty-six consenting adult 
patient’s propofol dose and effect site concentration at loss of verbal response 
were  recorded. It resolved that the effect site concentration of propofol alone 
was 2.19 µg mL -1 .This was reduced to 1.55 µg mL 1 during co-induction with 
remifentanil  and  further  reduced  to  0.64  µg  mL  -1 with  midazolam 
premedication.
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 It  was  concluded   that  co-induction  with  remifentanil  alone  or  with 
midazolam can be used to reduce propofol doses at induction of anaesthesia 
using target-controlled infusions.  
Yukihiro  Yoshida   1  ,  et  al   study  in  2001  to  determine  whether  propofol 
reduces extracellular concentrations of dopamine in the rat nucleus accumbens 
and  if  so,  whether  this  effect  is  potentiated  by  midazolam..  The  study 
demonstrated that propofol dose-dependently reduced dopamine release in rat 
nucleus accumbens, and that the effect was facilitated by midazolam; a similar 
interaction is also seen clinically, on preoperative anxiety and on anaesthesia
Cressey DM  ,  etal   2001 in  a  double-blind,  randomised  trial,  compared the 
effects of pretreatment with midazolam at two different doses (0.025 and 0.05 
mg / kg with placebo, on the induction dose requirements of propofol in two 
different  age groups.  60 younger patients (aged 18-35 years)  and 60 older 
patients  (aged  over  60  years).  All  patients  received  0.75  microg  /  kg  of 
fentanyl, plus a blinded pretreatment with either saline or one of two doses of 
midazolam. Induction continued with a fixed rate infusion of propofol. 
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Propofol dose requirement was recorded, as were cardiovascular parameters 
and the occurrence of significant apnoea (> 60 s). Midazolam pretreatment 
was associated with a significant reduction in propofol dose requirement in 
both  younger  and  older  patients.  The  reduction  in  older  patients  was 
significantly greater than the equivalent response in younger groups. There 
was no demonstrable benefit in terms of improved cardiovascular stability or 
reduction in the incidence of apnoea. One should be cautious in the use of 
midazolam as an agent for co-induction with propofol in the elderly.
Stegmann,  G.F.  et  al   (2001).  in  a  clinical  trial,  induced anaesthesia  with 
propofol  (4  mg/kg)  after  intravenous  premedication  with  or  without 
midazolam  (0.1  mg/kg),  in  a  group  of  8  dogs  scheduled  for 
ovariohysterectomy.
 Midazolam administration induced acute behavioral changes, and increased 
reflex suppression after propofol induction. Compared to the control group, 
the dose required to obtain loss of the pedal reflex was significantly reduced 
by  37%,  and  the  end-tidal  isoflurane  concentration  during  maintenance, 
reduced by 23%.
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MATERIALS AND METHODS
The  study  was  done  at Government  General  Hospital,  Madras  Medical 
College,  Chennai  after  getting  permission  from the  ethical  committee.  All 
patients gave informed consent. Both the patient and observer were unaware 
of the group allocations.
INCLUSION CRITERIA
ASA 1 and 2 patients
Age 16 to 50 years
Elective surgeries
EXCLUSION CRITERIA
ASA 3 and 4patients
Age <15years >50 years
Any co morbid illnesses
Patients on benzodiazepines
Ninety ASA1 patients age 16-50 years scheduled for elective surgery were 
studied.  All  patients  were  pre  operatively  investigated  for  baseline 
investigations  like  blood sugar,  urea,  serum creatinine ,ECG in 12 leads, 
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chest x-ray PA view and other specific investigations relevant to the disease. 
All patients were assessed for their physicl status.
 The subjects were not pre medicated and were randomly allocated to one of 
the three groups.
Group1 received midazolam 2 mg 2min prior to induction
Group 2 received propofol 30 mg 2min prior to induction
Group 3 received 3ml of 0.9%saline 2min prior to induction of anaesthesia. 
This was given as a bolus over a few seconds. Patients were counseled about 
the method of study.
Baseline  measurement  of  Blood pressure,  heart  rate and oxygen saturation 
were made prior to insertion of a 18 gauge venflon and these were repeated at 
60 seconds intervals for the reminder of the study. Anaesthesia was induced 
by infusing 1% propofol. Patients were encouraged to flex their arms to the 
command of the observer .and the blood pressure and heart rate were recorded 
simultaneously if  there was no response to verbal command.  The propofol 
infusion was stopped at this point and face mask applied firmly. Any response 
to placement of the mask was noted. The study was deemed complete at this 
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point and taken as the end point of induction. Induction dose of propofol was 
noted at this point.. And further management was not influenced by the study. 
OBSERVATIONS AND RESULTS
90 patients were taken up for the study.
Group 1 30 patients Group 2 30 patients and Group 3 30 patients.
Group1 received midazolam 2 mg 2min prior to induction
Group 2 received propofol 30 mg 2min prior to induction
Group 3 received 3ml of 0.9%saline 2min prior to induction of anaesthesia.
STATISTICAL ANALYSIS
Chi-square test
Paired t-test
ANOVA F-test
Multiple comparison by Bonferroni t- test
Qualitative data (sex,weight age) were were given  in frequencies with their 
percentages
Quantitative data (systolic blood pressure, pulse rate, dosage)were given in 
mean and standard deviation.
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Differences between the three groups on systolic bloodpressure, pulse rate 
were analysed using one way analysis of variance(ANOVA) and multiple 
comparison was done by using BONFERRONI TEST
Comparison between each group pre and post induction values were analysed 
using PAIRED T TEST
Demographic data (age ,sex.weight) between the groups were analysed using 
PEARSON CHI SQUARE TEST
Table 1: Demographic Profile
 
 
Group 1 Group 2 Group 3
Midazolam Propofol Control
Mean SD Mean SD Mean SD
Age 29.37 6.18 30.93 6.43 33.03 7.35
Wt 46.17 6.06 42.03 7.78 48.33 7.82
ASA 1.00 .00 1.00 .00 1.00 .00
SBP(baseli
ne) 128.27 5.51 127.30 4.91 128.90 4.47
DBP 80.60 2.67 83.43 4.70 82.53 3.93
PR 88.20 6.33 86.23 6.58 89.03 4.64
SBP(pre-
induction) 127.20 3.88 126.70 5.00 128.37 4.60
DBP 80.37 3.89 83.23 5.50 81.67 4.16
PR 86.70 5.09 83.53 6.77 87.63 4.54
SBP(post-
induction) 118.43 3.46 114.27 4.56 115.00 4.85
DBP 75.93 3.23 73.13 3.67 72.33 3.86
PR 78.73 4.43 74.67 5.77 74.63 4.12
Dosage 74.83 7.82 68.83 6.65 103.50 14.09
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Sex
Male Female
n % n %
group Midazolam
17 37.8 13 28.9
 Propofol
16 35.6 14 31.1
 control
12 26.7 18 40.0
χ2=1.86  P=0.39 not significant
Sex wise there is no significant differences between three groups. Male and 
female ratio is equal in all three groups(x2=1.86 p=0.39) 
 
  50
17
13
16
14 12
18
0
5
10
15
20
N
o.
 o
f p
at
ie
nt
s
Midazolam Propofol control
SEX DISTRIBUTION
male
female
 Age 
N Mean Std. Deviation
ANOVA
F-test
Midazolam
30 29.37 6.184
Propofol
30 30.93 6.432
control
30 33.03 7.351
F=2.28
P=0.11
Age wise there is no significant differences between the three groups (p=0.11) 
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AGE DISTRIBUTION
Weight 
N Mean Std. Deviation
ANOVA 
F-test
Midazolam
30 46.17 6.058
Propofol
30 42.03 7.784
control
30 48.33 7.818
F=5.82
P=0.01
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In weight distribution there was significant difference between group1 and 
group2as well as group2 and group3 (p=0.01) 
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WEIGHT  DISTRIBUTION
Descriptives
SYSTOLIC BLOOD PRESSURE-DIFFERENCE
 N Mean
Std. 
Deviation
ANOVA 
F-test Minimum Maximum
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Midazolam 30 8.7667 2.17641
Propofol 30 12.4333 3.29768
control 30 13.3667 2.59287
F=23.82
P=0.001
4.00 13.00
8.00 19.00
8.00 21.00
Multiple Comparisons
Dependent Variable: SBP_DIFF 
Bonferroni t-test
(I) group (J) group Mean Difference (I-J)
   
Midazolam Propofol -3.6667(*)
 control -4.6000(*)
Propofol Midazolam 3.6667(*)
  COMPARISON OF  SYSTOLIC BLOOD PRESSURE
(Before and After inducation) 
controlPropofolMidazolam
SB
P 
(in
 m
m
 H
g)
140
130
120
110
100
Pre induction
Post induction
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 control -.9333
control Midazolam 4.6000(*)
 Propofol .9333
• The mean difference is significant at the .05 level.
•
There was significant difference in systolic blood pressure before and after 
induction between group 1 and group 2as well as group 2 and group3 
(p=0.001)
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COMPARISON OF PULSE RATE
(Pre and Post induction)
controlPropofolMidazolam
Pu
ls
e 
ra
te
 (p
er
 m
in
)
110
100
90
80
70
60
PR-pre
PR-post
Pulse rate
group  Mean N
Std. 
Deviation
Paired
 t-test
Midazolam
 
PR-pre 86.70 30 5.093
PR-post 78.73 30 4.425
t=12.86
P=0.001
Propofol
 
PR-pre 83.53 30 6.766
PR-post 74.67 30 5.774
t=11.94
P=0.001
control
 
PR-pre 87.63 30 4.537
PR-post
74.63 30 4.123
t=23.51
P=0.001
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PULSE RATE DIFFERENCE
       
Midazola
m 30 7.9667 2.44221
Propofol 30 8.8667 4.06612
control 30 13.0000 3.02860
F=20.47
P=0.001
4.00 14.00
1.00 17.00
6.00 19.00
There was significant reduction in pulse rate between the control group and 
the other two groups(f=20.47,p=0.001)
Multiple Comparisons
Dependent Variable: PR_DIFF Bonferroni t-test
*  The mean difference is significant at the .05 level.
(I) group (J) group
Mean Difference 
(I-J)
   
Midazolam Propofol -.9000
 control -5.0333(*)
Propofol Midazolam .9000
 control -4.1333(*)
control Midazolam 5.0333(*)
 Propofol 4.1333(*)
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Descriptives
DOSAGE 
 N Mean
Std. 
Deviation
ANOVA
 F-test Minimum Maximum
      
Midazolam 30 74.83 7.822
Propofol 30 68.83 6.654
control 30 103.50 14.090
F=101.63
P=0.001
65 100
55 80
80 130
DOSAGE 
N Mean SD
ANOVA
 F-test
Midazola
m 30 74.83 7.822
Propofol 30 68.83 6.654
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Multiple Comparisons
Dependent Variable: DOSAGE 
Bonferroni 
(I) group (J) group
Mean 
Differenc
e (I-J) Sig.
Midazola
m
Propofol 6.00 .070
 control -28.67(*) .000
Propofol Midazola
m -6.00 .070
 control -34.67(*) .000
control Midazola
m 28.67(*) .000
 Propofol 34.67(*) .000
* 
 The mean difference is significant at the .05 level. The dosage requirement in 
midazolam group(1) was (mean=74.83 mgs),propofol predosing group(2) was 
(mean=68.83 mgs) and control group3 was ( mean=103.50 mgs) which was 
significant(p=0.001).
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Discussion
The  dose  of  propofol  required  to  induce  anaesthesia  depends  on  several 
variables – the end point used34, the age of the patient 6, the rate of injection 6, 
and the use of pre medication 8. Pre dosing with midazolam16 has been shown 
to be reliable and effective method of reducing propofol requirement  9. We 
have shown that predosing with 30 mg of propofol is as effective in reducing 
the induction dose of propofol as co induction with 2 mg of midazolam when 
loss of verbal contact is taken as end point.  In our study the induction dosage 
were  reduced  by  36%  in  group  1(midazolam  group)  and  32%  in  group2 
(propofol predosing group).The combination having  1.35 times the potency 
of individual agents.  
Short  TG.  et  al  in  1991  studied  interactions  between  IV  propofol  and 
midazolam  for  induction  of  anaesthesia  in  200  unpremedicated  female 
patients  undergoing  elective  gynaecological  surgery  using  end  points  of 
hypnosis  (loss  of  response  to  verbal  command)  and  anaesthesia  (loss  of 
response to 5-s transcutaneous tetanic stimulus)  and found that  synergestic 
interaction was found.
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 The combination having 1.44 times the potency of the individual agents. The 
dose of propofol required to produce anaesthesia was reduced by 52% in the 
presence of midazolam In our study the induction dosage were reduced by 
36% in group 1(midazolam group) and 32% in group2 (propofol predosing 
group).The combination having  1.35 times the potency of individual agents
Caba F. et al in 1993 studied the synergism of midazolam and propofol in the 
induction of anaesthesia. A double blind study of 90 ASA 1 and 2 women 
undergoing elective surgery revealed the ED 50 in propofol group was 1.56 
mg/kg  and  that  of  midazolam  group  was  0.24  mg/kg.  In  the  midazolam 
propofol group the ED 50 of midazolam was reduced approximately quarter 
0.068 mg/kg..In our study the induction dosage were reduced by 36% in group 
1(midazolam  group)  and  32%  in  group2  (propofol  predosing  group).The 
combination having  1.35 times the potency of individual agents In our study 
the induction dosage were reduced by 36% in group 1(midazolam group) and 
32% in  group2  (propofol  predosing  group).The  combination  having   1.35 
times the potency of individual agents
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AndersonLetalin 1999 in a double-blind, placebo-controlled study of 90 ASA 
1 and 2 patients scheduled for elective surgery compared the effect of pre-
administering midazolam 2 mg or propofol 30 mg on the dose of propofol 
subsequently required to induce anaesthesia.
 Using loss of response to verbal command and tolerance to placement of a 
facemask as end-points, the dose of propofol required to induce anaesthesia 
was  significantly  smaller  in  the patients  given propofol  (1.87  mg.kg-1)  or 
midazolam  (1.71  mg.kg-1)  when  compared  to  the  control  group  (2.38 
mg.kg-1).In our study the dosage requirement in midazolam group(1)(n=30) 
was (mean=74.83 mgs),propofol predosing group(2)(n=30) was (mean=68.83 
mgs)  and  control  group3  (n=30)was  (  mean=103.50  mgs)  which  was 
significant (p=0.001).
Cressey DM  ,  etal 2001 compared the effects of pretreatment with midazolam 
at two different doses (0.025 and 0.05 mg /kg) with placebo, on the induction 
dose  requirements  of  propofol  in  two  different  age  groups.:  60  younger 
patients (aged 18-35 years) and 60 older patients (aged over 60 years)
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It  was  concluded  that  Midazolam  pretreatment  was  associated  with  a 
significant reduction in propofol dose requirement in both younger and older 
patients.  The  reduction in  older  patients  was  significantly  greater  than the 
equivalent response in younger groups..Hence one should be  Cautious is in 
the  use  of  midazolam  as  an  agent  for  co-induction  with  propofol  in  the 
elderly. Hence in our study the age group selected for the study were between 
16 to 50 years.
 Reinhart DJ, etal. in 1997 compared the hemodynamics, efficacy, safety, and 
postoperative recovery of patients following the use of either midazolam plus 
propofol or placebo plus propofol for induction and maintenance of general 
anesthesia for outpatient surgical procedures of less than two hours' duration: 
The study. included 203 ASA I, II, and III patients undergoing various 
outpatient surgical procedures. It was concluded that concomitantly 
administered midazolam and reduction-concentration propofol did not 
exacerbate the well-described hypotensive effects of full-strength propofol 
during induction of anesthesia
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In our study. there was significant reduction in systolicblood pressure between 
group1 and group2 as well as group1 and group3.(p=0.001) There was 
significant reduction in pulse rate between the control group and the other two 
groups(f=20.47,p=0.001).
Although  midazolam  may  work  synergistically  with  propofol51,  a  major 
clinical benefit is the rapid attainment of anxiolysis. We did not attempt to 
quantify or compare the anxiolysis achieved by the administration of either 
midazolam or  propofol  but  the  patients  appeared  to  be  more  relaxed  and 
settled and the associated reduction in sympathetic drive may have allowed 
induction  of  anaesthesia  with  lower  doses  of  propofol.  Pre  dosing  and co 
induction  both  reduce  the  dose  of  induction  agent  required  to  achieve 
hypnosis and any form of pre medication is likely to have similar effect 47.
Both midazolam and propofol groups(Group1&2) are therefore cost effective, 
in  that  the  propofol  requirements  in  our  study  where  limited  to  a  single 
ampoule  for  each  patient.  Pre  dosing  with  propofol  is  as  effective  as 
midazolam in reducing the dose of propofol to induce anaesthesia
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We used two end points – loss of response to verbal command and response to 
placement  of  face  mask.  Of  these  we  found  loss  of  response  to  verbal 
command the more  reproducible.  However  if  we had used a  different  end 
points such as laryngeal mask insertion 34 the results may have been different. 
Our study was blinded, the assessor being unaware of the pre dosing agent, 
and we consider this essential for any objective assessment.
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SUMMARY
In this study pre dosing of 2 mg of midazolam as co-induction agent  
( group 1) where propofol is used as an  induction agent  had Lesser blood 
pressure variability and Lesser heart rate variability during and after 
induction. Midazolam co-induction is more cost effective than control  (group 
3) ,since it requires only a single vial of propofol for induction.
Pre dosing of 30 mg of propofol(Group 2)   before propofol induction had 
Reduced dosage requirement, lesser blood pressure variability, lesser heart 
rate variability  than group 3( control group).It is more cost effective than the 
control group and midazolm co-induction.
control group (Group 3)  is less cost effective than the other two groups, since 
it  requires more than one vial of propofol for induction. It produces more 
hemodynamic variability which is statically significant. when compared with 
the other two groups. 
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CONCLUSION
Predosing  of  midazolam  for  propofol  induction  had  less  hemodynamic 
variability (fall in blood pressure and heart rate during and after induction) 
and  more  cost  effective  since  it  requires  only  single  vial  of  propofol  for 
induction,  whereas  control  group  had  significant  hemodynamic  variability 
,significant fall in blood pressure and heart rate  .and requires more than a 
single  vial of propofol for induction, hence it is not cost effective..
Predosing  of  propofol  for  induction  with  propofol  had  less  hemodynamic 
variability(fall in blood pressure and heart rate) than the control group.  It is 
more  cost  effective   when compared  to  control  group and midazolam co-
induction group.
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PROFORMA
A comparison of midazolam co induction with propofol predosing for 
induction of anaesthesia
Aim:
            Comparing the effect of preadministering midzolm 2mg with propofol 
30 mg on the dose of propofol required subsequently to induce anaesthesia 
Inclusion criteria:
                                 ASA1&2 patients
                                   Age 16 to 50 years
                                   Elective surgeries
Exclusion criteria:
                               ASA 3& 4 patients
                                 Any co morbid illnesses
                                 Patients on oral benzodiazepines
NAME :
AGE :
SEX :
WEIGHT :
ASA status :
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MONITORS :
                          Systolic blood pressure before and after induction
                          Heart rate before and after induction
                            Propofol induction dosage (mg/kg)
GROUP 1 :MIDAZOLM GROUP (n=30)
GROUP 2 :PROPOFOL PREDOSING GROUP(n=30)
GROUP 3 :CONTROL GROUP (n=30)
METHOD :
                      Administering either midazolam 2mgs or propofol 30 mgs or 3 
ml of 0.9%norml saline two minutes before induction
End point of induction:
                                       1. Loss of response to verbal command
                                       2. Tolerance to placement of face mask 
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Group 1
Name IP No. Age Sex Wt ASA Pre Op Pre 
Induction
Post 
Induction
BP PR BP P
R
BP PR
Propofol 
Dose
Comments
darmajirao 77285
3
28 M 65 1 150/80 10
9
136/84 10
0
123/78 92 100
aswinidevi 76818
2
19 F 45 1 130/78 98 130/76 94 120/70 88 75
alamelu 76523
4
25 F 48 1 128/80 92 128/80 90 122/72 82 80
balasundaram 75326
1
32 M 50 1 132/80 95 130/80 94 118/78 80 85
selvi 74342
2
26 F 42 1 126/82 89 126/88 86 118/76 78 75
maragatham 75482
1
36 F 46 1 134/82 89 134/88 88 125/78 80 80
jayanthi 76243
1
21 F 38 1 120/78 82 120/76 83 116/72 75 70
paramasivam 75441
1
30 M 55 1 130/84 90 130/82 89 122/78 81 85
saraswathy 75488
9
35 F 45 1 128/79 86 128/78 89 120/75 80 75
gomathy 74562
1
28 F 42 1 130/79 81 130/78 80 121/78 74 80
vinoth 75841
2
18 M 35 1 120/76 82 120/75 83 112/70 72 65
nagaraj 74254
1
24 M 50 1 126/84 85 126/84 82 118/76 78 85
chandrakala 75266
3
30 F 49 1 125/84 86 126/86 84 120/78 80 85
shanthi 74963
2
27 F 38 1 130/76 93 130/75 95 121/80 85 65
shankar 75826
1
30 M 52 1 125/79 89 124/78 86 118/75 81 80
anand 73521
9
19 M 46 1 126/78 75 126/74 76 118/70 72 75
lakshmipathy 74316
5
28 M 39 1 130/78 86 130/78 84 121/70 79 70
rani 75269
8
33 F 45 1 129/84 84 129/84 81 118/78 76 70
amudha 74441
2
29 F 46 1 125/80 90 125/82 86 119/76 78 75
boopathy 74326 30 M 53 1 132/84 86 130/82 84 118/80 76 75
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9
jeyapradapan 73956
9
42 M 48 1 129/84 84 129/84 85 120/78 75 70
kumar 74412
3
26 M 38 1 130/79 84 130/78 84 119/76 78 65
kaliamoorthy 73956
2
41 M 48 1 128/79 92 126/76 90 118/72 81 70
anand 74114
2
29 M 46 1 131/82 89 130/82 85 124/76 75 70
thirunavukkarasu 75841
2
25 M 50 1 126/82 94 125/81 92 116/78 80 75
rathidevi 74139
8
29 F 48 1 130/85 92 125/84 90 113/79 81 70
sushanthkumar 73998
4
36 M 46 1 125/79 86 125/78 85 116/79 75 70
farooq 74698
2
40 M 38 1 118/79 80 118/78 81 110/74 74 65
sathya 75839
1
35 F 35 1 132/81 95 132/80 92 124/74 78 65
suresh 73333
1
29 M 46 1 126/78 85 125/75 84 110/70 70 70
Group 2
Name IP No. Age Sex Wt ASA Pre Op Pre 
Induction
Post 
Induction
BP PR BP PR BP PR
Propofol 
Dose
Comments
Kumar 741256 35 M 45 1 125/86 89 125/87 85 110/74 74 70
aravinth 732589 28 M 43 1 130/92 96 130/96 95 114/80 80 70
aswin 749856 27 M 35 1 129/78 85 128/76 87 116/71 70 65
mallika 725869 30 F 38 1 125/86 89 125/86 88 115/74 80 65
manohar 741090 45 M 56 1 130/89 86 130/88 85 120/76 78 80
kalpana 731111 29 F 30 1 129/76 95 129/78 92 119/71 84 60
rajesh 746103
2
27 M 45 1 135/84 92 134/86 91 120/79 80 70
ramya 736185 24 F 38 1 129/85 91 129/86 90 110/78 82 65
settu 744658 35 M 48 1 125/90 86 126/89 79 112/74 78 70
loganathan 748547 41 M 56 1 131/86 82 130/87 80 120/74 71 80
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indira 741767 29 F 30 1 126/87 81 126/89 79 110/70 70 60
uma 746980 35 F 39 1 124/74 80 124/75 76 108/70 69 65
ganesh 736770 31 M 47 1 126/84 79 126/86 80 113/76 71 70
williams 739500 46 M 51 1 135/82 78 135/80 81 120/79 70 80
sakunthala 725021 29 F 35 1 126/84 91 125/85 89 116/70 81 65
selvi 741399 25 F 40 1 124/80 94 123/79 85 114/72 80 65
ranjith 726262 31 M 48 1 130/78 89 128/76 90 115/70 78 75
premkumar 736560 26 M 40 1 126/89 76 127/90 80 109/79 65 70
ravi 751020 31 M 46 1 132/90 93 130/90 90 119/80 84 75
easwari 741335 21 F 30 1 118/78 85 118/76 81 109/69 79 60
banu 736699 28 F 35 1 119/80 75 118/79 72 110/71 69 65
vijay 728846 36 M 50 1 129/90 81 128/86 76 112/69 70 80
sangeetha 719890 20 F 27 1 119/80 94 117/79 89 108/70 75 55
kishore 736251 24 M 42 1 124/85 86 123/86 81 113/70 71 65
jamuna 749821 30 F 40 1 125/84 84 124/83 79 114/69 70 65
vijaya 746094 36 F 45 1 135/85 96 134/82 90 121/71 81 70
nithya 739104 25 F 48 1 119/78 78 117/76 70 109/70 67 70
palani 721560 40 M 53 1 136/84 76 135/86 70 118/74 65 80
Group 3
Name IP No. Age Sex Wt ASA Pre Op Pre 
Induction
Post 
Induction
BP PR BP PR BP PR
Propofol 
Dose
Comments
Murugan 74656
6
35 M 45 1 125/78 96 124/75 94 109/70 78 100
Thangam 73965
2
30 F 38 1 130/80 89 129/85 88 121/74 74 90
Easwari 74144
4
25 F 40 1 124/80 85 124/79 83 108/73 70 95
Jamuna 73865
2
24 F 43 1 125/84 84 121/80 80 108/69 71 100
Reeta 74465
1
25 F 39 1 126/85 85 125/84 86 110/71 72 90
Raju 73392 40 M 56 1 130/87 90 132/88 88 120/79 79 100
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1
Grace 73895
2
35 F 48 1 131/79 86 130/80 85 119/69 71 100
Mani 73652
4
40 M 60 1 136/84 87 135/82 85 120/74 79 130
Nithya 73874
5
29 F 35 1 124/78 79 124/76 78 109/78 68 80
Kavitha 73872
1
27 F 46 1 126/80 87 125/79 85 112/70 74 90
Manjula 73877
9
30 F 48 1 130/79 85 130/78 83 117/69 75 100
Jeya 73865
9
40 F 50 1 135/78 86 134/76 85 120/79 74 110
Arumugam 73854
7
48 M 57 1 136/89 95 135/87 93 121/78 79 120
Suguna 73849
8
35 F 47 1 124/79 84 124/78 83 108/67 70 100
Ramya 74102
0
26 F 39 1 121/80 86 120/79 85 108/69 68 90
Selvam 74005
6
35 M 60 1 130/91 93 130/90 91 112/78 80 130
Hari 74115
8
25 M 52 1 135/86 92 135/85 90 120/79 78 110
Banu 74698
5
28 F 47 1 129/84 90 128/83 89 117/70 70 100
Gomathy 73801
4
30 F 48 1 131/82 89 130/81 88 118/69 71 100
Deepa 74003
1
27 F 46 1 129/86 93 128/85 92 117/72 78 100
Mohan 74501
2
30 M 50 1 132/85 92 131/84 91 120/70 76 110
Sundaram 73905
0
45 M 58 1 129/87 94 129/86 90 117/71 78 120
Jareena 73912
8
26 F 39 1 119/78 81 119/78 80 108/69 70 80
Francis 73894
7
35 M 50 1 130/84 92 130/82 90 119/74 75 110
Hamsaveni 73645
8
29 F 45 1 128/79 96 128/78 95 113/69 80 100
David 74001
7
50 M 62 1 135/90 94 135/90 93 120/78 81 130
Lavanya 74025
8
26 F 40 1 128/80 96 128/79 95 117/69 78 90
Moorthy 73910
5
35 M 59 1 135/85 92 135/85 91 114/74 80 120
Andal 74009 36 F 42 1 130/81 89 130/81 88 118/70 72 90
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5
Kuppan 74015
8
45 M 61 1 124/78 84 124/77 85 110/69 70 120
 
